Sangamo Therapeutics, Inc.

🧬🚀 We’ve made substantial progress in development of our modular integrase, or MINT, platform- a gene editing method that we believe will enable large-scale genome engineering. Our updated manuscript which showcases these advances is now available on bioRxiv at https://bit.ly/41Y14ud. Some key highlights: • We pair our MINT platform with known activity-increasing Bxb1 mutants and engineered zinc fingers to achieve up to 35% targeted integration at the clinically relevant human TRAC locus. • We demonstrate highly efficient targeted integration of a GFP expression cassette in primary human T cells. • We provide a curated library of pre-characterized Bxb1 DNA binding domains to enable broad adoption of our MINT platform. To explore our findings in full detail, click here - https://bit.ly/41Y14ud #genomicmedicine #genomeengineering #integrases #recombinases

At Sangamo, we’re dedicated to transforming lives through innovative science. In the latest edition of our "From the (Gene) Editor" newsletter, we highlight the promising potential of ST-920—a one-time, durable treatment option for people living with Fabry disease. Our goal is to bring genomic medicine treatments that advance our mission of improving lives through groundbreaking science. #GenomicMedicine #FabryDisease

On September 6, we will present @ #NeuPSIG2025 data highlighting the pharmacology and safety of ST-503 in  chronic neuropathic pain.   Using an engineered zinc finger repressor that specifically targets the SCN9A gene, we will show durability, potency, selectivity and safety in nonhuman primates, supporting the development of ST-503 for the treatment of chronic neuropathic pain.   We have initiated the first clinical site in the Phase 1/2 STAND study evaluating ST-503 and are excited to be identifying patients in our first ever neurology clinical study.   For more information, visit our Presentations page: https://bit.ly/4lY7xME #GenomicMedicine #NeuropathicPain #NeuPSIG2025

Today at the International Congress of Inborn Errors of Metabolism 2025 we were pleased to present detailed data from our registrational STAAR study in Fabry Disease.   The totality of the data supports the potential for ST-920 as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care.   Sangamo plans to submit a BLA in 2026 under the Accelerated Approval pathway. For more information, visit our Presentations page - https://bit.ly/4lY7xME #GenomicMedicine #FabryDisease #ICIEM2025

We’re proud to be advancing new opportunities for patients living with chronic neuropathic pain. We have initiated the first clinical site in the Phase 1/2 STAND study evaluating ST-503, our investigational epigenetic regulator for patients with intractable neuropathic pain caused by idiopathic small fiber neuropathy, or iSFN. This milestone marks an exciting step forward in our efforts to address this debilitating condition. We believe ST-503 represents a novel and non-opioid approach with the potential to offer lasting relief where few options exist today. We are excited to be identifying patients in our first ever neurology clinical study. 🔗 To learn more about the upcoming clinical trial, visit: https://bit.ly/45UwRhP #GenomicMedicine #Neurology #ChronicPain #NeuropathicPain

Today, we announce our second quarter 2025 financial results, showcasing important progress across our clinical and pre-clinical pipeline.   Learn more here: https://bit.ly/4m9BJWf #genomicmedicine #neurology #epigenetics #zincfinger #fabry

Our second quarter 2025 financial results will be announced on Thursday, August 7, 2025, with a conference call at 4:30 PM ET. Details on how to join: https://bit.ly/4l3gdkn

Today we are excited to share positive topline results for our registrational STAAR study in Fabry Disease. Following a single dose of ST-920 a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks was observed across all 32 dosed patients in the study, which the FDA has agreed will serve as the primary basis of approval. ST-920 also showed a favorable safety and tolerability profile.  Collectively these highly encouraging results demonstrate the potential for a single dose of ST-920 to provide meaningful clinical benefits above current standards of care and will form the basis for an anticipated BLA submission under the Accelerated Approval pathway as early as the first quarter of 2026. Learn more here: https://bit.ly/4ehdfqX #GenomicMedicine #FabryDisease

Join our CEO, Sandy Macrae, MRCP PhD, for a fireside chat at the H.C. Wainright 6th Annual Neuro Perspectives Hybrid Conference on Tuesday, June 17th at 7:00 a.m. EDT. For the latest information, visit our website: https://bit.ly/3sfJt2f #GenomicMedicine #Neurology

Join us for a webinar on June 5th demonstrating how we have combined the power of our potent zinc finger repressors (ZFRs) 🧬and our proprietary STAC-BBB capsid 🧠 to create a promising potential one-time intravenous treatment for prion disease.